Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
Perry Elliott, Brian M Drachman, Stephen S Gottlieb, James E Hoffman, Scott L Hummel, Daniel J Lenihan, Ben Ebede, Balarama Gundapaneni, Benjamin Li, Marla B Sultan, Sanjiv J Shah, Perry Elliott, Brian M Drachman, Stephen S Gottlieb, James E Hoffman, Scott L Hummel, Daniel J Lenihan, Ben Ebede, Balarama Gundapaneni, Benjamin Li, Marla B Sultan, Sanjiv J Shah
Abstract
Background: Tafamidis is approved in many countries for the treatment of transthyretin amyloid cardiomyopathy. This study reports data on the long-term efficacy of tafamidis from an ongoing long-term extension (LTE) to the pivotal ATTR-ACT (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Methods: Patients with transthyretin amyloid cardiomyopathy who completed ATTR-ACT could enroll in an LTE, continuing with the same tafamidis dose or, if previously treated with placebo, randomized (2:1) to tafamidis meglumine 80 or 20 mg. All patients in the LTE transitioned to tafamidis free acid 61 mg (bioequivalent to tafamidis meglumine 80 mg) following a protocol amendment. In this interim analysis, all-cause mortality was assessed in patients treated with tafamidis meglumine 80 mg in ATTR-ACT continuing in the LTE, compared with those receiving placebo in ATTR-ACT transitioning to tafamidis in the LTE.
Results: Median follow-up was 58.5 months in the continuous tafamidis group (n=176) and 57.1 months in the placebo to tafamidis group (n=177). There were 79 (44.9%) deaths with continuous tafamidis and 111 (62.7%) with placebo to tafamidis (hazard ratio, 0.59 [95% CI, 0.44-0.79]; P<0.001). Mortality was also reduced in the continuous tafamidis (versus placebo to tafamidis) subgroups of: variant transthyretin amyloidosis (0.57 [0.33-0.99]; P=0.05) and wild-type transthyretin amyloidosis (0.61 [0.43-0.87]; P=0.006); and baseline New York Heart Association class I and II (0.56 [0.38-0.82]; P=0.003) and class III (0.65 [0.41-1.01]; P=0.06).
Conclusions: In the LTE, patients initially treated with tafamidis in ATTR-ACT had substantially better survival than those first treated with placebo, highlighting the importance of early diagnosis and treatment in transthyretin amyloid cardiomyopathy. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01994889 and NCT02791230.
Keywords: amyloid; cardiomyopathies; heart failure; mutation; phenotype.
Figures
References
- Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, Biagini E, Salvi F, Branzi A. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010; 7:398–408. doi: 10.1038/nrcardio.2010.67
- Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019; 73:2872–2891. doi: 10.1016/j.jacc.2019.04.003
- Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011; 10:1086–1097. doi: 10.1016/S1474-4422(11)70246-0
- Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid. 2015; 22:171–174. doi: 10.3109/13506129.2015.1051219
- Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, Mosley TH, Butler KR, Boerwinkle E, Solomon SD. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015; 372:21–29. doi: 10.1056/NEJMoa1404852
- Shah KB, Mankad AK, Castano A, Akinboboye OO, Duncan PB, Fergus IV, Maurer MS. Transthyretin Cardiac Amyloidosis in Black Americans. Circ Heart Fail. 2016; 9:e002558. doi: 10.1161/CIRCHEARTFAILURE.115.002558
- Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, et al. . A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018; 39:2799–2806. doi: 10.1093/eurheartj/ehx589
- Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, et al. . Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012; 164:222–228.e1. doi: 10.1016/j.ahj.2012.04.015
- Givens RC, Russo C, Green P, Maurer MS. Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging Health. 2013; 9:229–235. doi: 10.2217/ahe.13.10
- Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A. Natural history of wild-type Transthyretin Cardiac Amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016; 68:1014–1020. doi: 10.1016/j.jacc.2016.06.033
- Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, et al. . Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA. 2012; 109:9629–9634. doi: 10.1073/pnas.1121005109
- Waddington Cruz M, Benson MD. A review of Tafamidis for the treatment of Transthyretin-related amyloidosis. Neurol Ther. 2015; 4:61–79. doi: 10.1007/s40120-015-0031-3
- Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, et al. ; ATTR-ACT Study Investigators. Tafamidis treatment for patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018; 379:1007–1016. doi: 10.1056/NEJMoa1805689
- VYNDAQEL and VYNDAMAX Highlights of Prescribing Information. . Accessed January 21, 2021.
- Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, Patterson TA, Riley S, Schwartz JH, Sultan MB, et al. . Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021; 23:277–285. doi: 10.1002/ejhf.2027
- Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, Gundapaneni B, Hahn C, Riley S, Schwartz J, et al. ; ATTR-ACT Study Investigators. Design and rationale of the phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Circ Heart Fail. 2017; 10:e003815. doi: 10.1161/CIRCHEARTFAILURE.116.003815
- Lockwood PA, Le VH, O’Gorman MT, Patterson TA, Sultan MB, Tankisheva E, Wang Q, Riley S. The bioequivalence of Tafamidis 61-mg free acid capsules and Tafamidis Meglumine 4 × 20-mg capsules in healthy volunteers. Clin Pharmacol Drug Dev. 2020; 9:849–854. doi: 10.1002/cpdd.789
- Li B, Alvir J, Stewart M. Extrapolation of survival benefits in patients with Transthyretin Amyloid Cardiomyopathy receiving Tafamidis: analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial. Cardiol Ther. 2020; 9:535–540. doi: 10.1007/s40119-020-00179-2
- Latimer N. NICE DSU Technical Support Document 14: Survival analysis for Economic Evaluations Alongside Clinical Trials - Extrapolation With Patient-Level Data. 2013. Accessed June 12, 2019.
- Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, Boman K, Gundapaneni B, Patterson TA, Schwartz JH, et al. . Efficacy of Tafamidis in patients with hereditary and wild-type Transthyretin Amyloid Cardiomyopathy: further analyses from ATTR-ACT. JACC Heart Fail. 2021; 9:115–123. doi: 10.1016/j.jchf.2020.09.011
Source: PubMed